PhaseBio Pharmaceuticals R&D Expenses

R&D Expenses of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including R&D Expenses growth rates and interactive chart. Research and development (R&D) expenses are associated with the research and development of a company's goods or services. A company generally incurs R&D expenses in the process of finding and creating new products or services. It is an operating expense and can be deducted from a company's income taxes.


Highlights and Quick Summary

  • R&D Expenses for the quarter ending June 29, 2021 was $27.4 Million (a 22.61% increase compared to previous quarter)
  • Year-over-year quarterly R&D Expenses increased by 57.13%
  • Annual R&D Expenses for 2020 was $72.1 Million (a 105.31% increase from previous year)
  • Annual R&D Expenses for 2019 was $35.1 Million (a 86.22% increase from previous year)
  • Annual R&D Expenses for 2018 was $18.9 Million (a 100.37% increase from previous year)
  • Twelve month R&D Expenses ending June 29, 2021 was $89.5 Million (a 7.85% increase compared to previous quarter)
  • Twelve month trailing R&D Expenses increased by 53.99% year-over-year
Trailing R&D Expenses for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$89.5 Million $83 Million $72.1 Million $58.1 Million
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical R&D Expenses of PhaseBio Pharmaceuticals

Most recent R&D Expensesof PHAS including historical data for past 10 years.

Interactive Chart of R&D Expenses of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals R&D Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $27.37 $22.32
2020 $22.37 $17.42 $20.86 $11.45 $72.09
2019 $8.38 $9.03 $7.78 $5.72 $35.11
2018 $5.68 $4.35 $3.19 $2.24 $18.86
2017 $1.33 $9.41
2016 $7.38

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.